Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Archives of Dermatology

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/archderm.144.6.727PMID 18559761
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.

  2006cited by this paper
• Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

  2006cited by this paper
• Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2

  2005cited by this paper
• Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

  2005cited by this paper
• Pegylated liposomal doxorubicin in stage IVB mycosis fungoides

  2005cited by this paper
• [Therapy algorithm for cutaneous T-cell lymphomas].

  2005cited by this paper
• Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.

  2005cited by this paper
• Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy

  2004cited by this paper
• Phase II study of pentostatin in advanced T‐cell lymphoid malignancies

  2004cited by this paper
• Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T‐cell lymphomas

  2003cited by this paper
• Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients.

  2003cited by this paper
• Long‐term remission of recalcitrant tumour‐stage mycosis fungoides following chemotherapy with pegylated liposomal doxorubicin

  2003cited by this paper
• Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma

  2003cited by this paper
• Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.

  2002cited by this paper
• Clinical uses of pegylated pharmaceuticals in oncology.

  2002cited by this paper
• Pegylated liposomal doxorubicin in the treatment of cutaneous T-cell lymphoma.

  2001cited by this paper
• A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T‐cell lymphoma

  2001cited by this paper
• A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form

  2001cited by this paper
• Liposomal encapsulated anthracyclines: new therapeutic horizons

  2001cited by this paper
• Eovist Injection and Resovist Injection: two new liver-specific contrast agents for MRI.

  2000cited by this paper
• Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.

  2000cited by this paper
• Treatment of erythrodermic cutaneous T‐cell lymphoma with intermittent chlorambucil and fluocortolone therapy

  2000cited by this paper
• Pentostatin treatment of cutaneous T-cell lymphoma.

  2000cited by this paper
• Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

  2000cited by this paper
• Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.

  2000cited by this paper
• Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin.

  2000cited by this paper
• Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group.

  1999cited by this paper
• Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T‐cell lymphoma

  1999cited by this paper
• Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP.

  1998cited by this paper
• Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.

  1998cited by this paper
• Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma.

  1997cited by this paper
• Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome.

  1997cited by this paper
• Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma.

  1997cited by this paper
• EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.

  1997cited by this paper
• Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma.

  1997cited by this paper
• Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.

  1996cited by this paper
• Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients.

  1996cited by this paper
• Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.

  1995cited by this paper
• Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.

  1994cited by this paper
• Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation.

  1993cited by this paper
• Repulsive interactions and mechanical stability of polymer-grafted lipid membranes.

  1992cited by this paper
• Pentostatin induces durable remissions in hairy cell leukemia.

  1991cited by this paper
• Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo.

  1991cited by this paper
• Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study.

  1990cited by this paper
• A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.

  1989cited by this paper
• Low-dose methotrexate for the Sézary syndrome.

  1989cited by this paper
• Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study.

  1988cited by this paper
• Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.

  1987cited by this paper
• Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.

  1987cited by this paper
• Systemic polychemotherapy in patients with mycosis fungoides and lymph node involvement: a follow-up study of 17 patients.

  1985cited by this paper
• Combination chemotherapy for mycosis fungoides with cyclophospriamide, vincristine, methotrexate, and prednisone

  1984cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas.

  1979cited by this paper
• Treatment of Sezary syndrome.

  1974cited by this paper

• Folliculotropic Mycosis Fungoides: Update on Diagnosis, Clinicopathological Stage, and Management

  2026cites this paper
• Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025

  2025cites this paper
• [Cutaneous T-cell lymphomas].

  2024cites this paper
• Classical and biological treatments in mycosis fungoides/Sézary syndrome. New horizons in oncodermatology

  2024cites this paper
• Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas

  2023cites this paper
• Harnessing the immune system in the treatment of cutaneous T cell lymphomas

  2023cites this paper
• Suggested Guidelines for the Treatment of Mycosis Fungoides in Countries with Limited Resources

  2023cites this paper
• Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments

  2023cites this paper
• Mycosis Fungoides: Case report of progression successfully treated with liposomal doxorubicin

  2023influential citation
• Mycosis fungoides with spongiosis: a case report

  2023cites this paper
• What Is New in Cutaneous T Cell Lymphoma?

  2023cites this paper
• Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study

  2022cites this paper
• Real‐life experience of using pegylated liposomal doxorubicin in primary cutaneous T‐cell lymphomas

  2022cites this paper
• Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy

  2021cites this paper
• How we treat mycosis fungoides and Sézary syndrome.

  2021cites this paper
• Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas

  2021cites this paper
• The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T‐cell lymphoma

  2020cites this paper
• Novel Therapeutics for Rare Lymphomas

  2020cites this paper
• Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity

  2020cites this paper
• The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review

  2020cites this paper
• NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

  2020cites this paper
• Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020

  2020cites this paper
• Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sézary Syndrome

  2019cites this paper
• Cutaneous Lymphomas.

  2019cites this paper
• Kutane Lymphome

  2019cites this paper
• Mycosis Fungoides and Sézary Syndrome: An Update.

  2019cites this paper
• An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma

  2018cites this paper
• Mycosis Fungoides in Critically Ill Cancer Patients

  2018cites this paper
• Classification and recommended treatment options for folliculotropic mycosis fungoides

  2018cites this paper
• Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome

  2018cites this paper
• Therapie der Mycosis fungoides und des Sézary-Syndroms

  2017cites this paper
• Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients

  2017cites this paper
• Focal Pegylated Liposomal Doxorubicin-Induced Urticarialike Reaction at Cutaneous Transformed Sézary Lesions.

  2017cites this paper
• European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.

  2017cites this paper
• King’s Research Portal

  2017cites this paper
• Lymphomes cutanés

  2017cites this paper
• Primary cutaneous lymphomas – diagnostic and therapeutic guidelines of the Polish Dermatological Society

  2017cites this paper
• Mycosis Fungoides and Sezary Syndrome.

  2017cites this paper
• Cutaneous T‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and management

  2017cites this paper
• How I treat mycosis fungoides and Sézary syndrome.

  2016cites this paper
• Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.

  2016cites this paper
• T-cell lymphomas, a challenging disease: types, treatments, and future

  2016cites this paper
• Cutaneous T‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management

  2016cites this paper
• Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.

  2016cites this paper
• A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome

  2016cites this paper
• Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma

  2016cites this paper
• Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.

  2015cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) ® Non-Hodgkin ’ s Lymphomas

  2015cites this paper
• Practical Management of CD30⁺ Lymphoproliferative Disorders.

  2015cites this paper
• CME Information: Cutaneous T-cell lymphoma: 2016 Update on diagnosis, risk-stratification, and management

  2015cites this paper
• Systematic review of combination therapies for mycosis fungoides.

  2014cites this paper
• Cutaneous T-Cell Lymphoma

  2014cites this paper
• Sézary syndrome: an overview of current and future treatment options

  2014influential citation
• Linfomas T cutáneos de tipo micosis fungoide/síndrome de Sézary (incluida parapsoriasis)

  2014cites this paper
• Lymphomes T cutanés type mycosis fongoïde/syndrome de Sézary (incluant parapsoriasis)

  2014cites this paper
• CME Information: Cutaneous T-cell lymphoma: 2014 Update on diagnosis, risk-stratification, and management

  2014cites this paper
• Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma.

  2014cites this paper
• Systemic Treatment of Primary Cutaneous Lymphomas

  2014cites this paper
• Management kutaner Lymphome

  2014cites this paper
• Cutaneous T‐cell lymphoma: 2014 Update on diagnosis, risk‐stratification, and management

  2014cites this paper
• Treatment of advanced cutaneous T‐cell lymphomas with non‐pegylated liposomal doxorubicin – Consensus of the lymphoma group of the Working Group Dermatologic Oncology

  2013cites this paper
• Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma

  2013cites this paper
• [National guidelines of diagnosis and treatment of the non-Hodgkin lymphoma].

  2013cites this paper
• Mycosis fongoïde érythrodermique et syndrome de Sézary

  2013cites this paper
• Recommandations pour le traitement des lymphomes T cutanés

  2013cites this paper
• Cutaneous T-cell lymphoma in sub-Saharan Africa.

  2013cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation

  2013cites this paper
• Guias nacionales de diagnóstico y tratamiento de linfoma no Hodgkin

  2013cites this paper
• Therapie der fortgeschrittenen kutanen T‐Zell‐Lymphome mit nichtpegyliertem liposomalem Doxorubicin – Konsensus der Lymphomgruppe der Arbeitsgemeinschaft Dermatologische Onkologie

  2013cites this paper
• Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012.

  2012cites this paper
• Actualización terapéutica en linfomas cutáneos

  2012cites this paper
• Actualités sur le syndrome de Sézary New developments in Sézary syndrome

  2012cites this paper
• [New developments in Sézary syndrome].

  2012cites this paper
• Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma

  2012cites this paper
• Emerging treatment options for advanced-stage mycosis fungoides.

  2012cites this paper
• Cutaneous T cell lymphoma: update on treatment

  2012cites this paper
• Treatment of cutaneous lymphomas: an update.

  2012cites this paper
• Highlights in T-cell lymphoma from the 2011 American Society of Hematology Annual Meeting and Exposition.

  2012cites this paper
• Recent advances in the management of cutaneous lymphomas.

  2012cites this paper
• Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.

  2012cites this paper
• [Cutaneous lymphoma at the Dermatology Day conference, Paris 2010].

  2011cites this paper
• Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas

  2011cites this paper
• Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

  2011cites this paper
• Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

  2011cites this paper
• Les lymphomes cutanés aux Journées Dermatologiques de Paris 2010

  2011cites this paper
• Treatment algorithms for mature T-cell and natural killer-cell neoplasms.

  2011cites this paper
• Safety and efficacy of interferon-alfa2b (IFN) in the treatment of patients with mycosis fungoides

  2011cites this paper
• Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cites this paper
• Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cites this paper
• Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma ( CSLL-1 Follicular Lymphoma ( FOLL-1 Mantle Cell Lymphoma ( MANT-1 Diffuse Large B-Cell Lymphoma ( BCEL-1 Burkitt Lymphoma ( BURK-1 Lymphoblastic

  2010cites this paper
• Maligne Lymphome der Haut — Update zu Diagnostik und Therapie

  2010cites this paper
• [Management of cutaneous T-cell lymphomas: Recommendations of the French Cutaneous Lymphoma Group].

  2010cites this paper
• Leczenie pierwotnych chłoniaków skóry. Rekomendacje Sekcji Chłoniaków Skóry Polskiej Grupy Badawczej Chłoniaków (PLRG) The treatment of primary cutaneous lymphoma. Recommendations of the Polish Lymphoma Research Group (PLRG)

  2010cites this paper
• Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.

  2010cites this paper
• Prise en charge des lymphomes T cutanés : recommandations du Groupe français d’étude des lymphomes cutanés

  2010cites this paper
• Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

  2009cites this paper
• How I Treat How I treat mycosis fungoides and Sézary syndrome

  2009cites this paper
• Primary Cutaneous T‐cell Lymphoma

  2009cites this paper
• Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides.

  2009cites this paper